| Autor: |
Mangala, S. L., Armaiz-Pena, G. N., Lopez-Berestein, G., Gharpure, K. M., Rupaimoole, R., Luft, J. C., Wu, S. Y., Chu, K. S., Bowerman, C. J., Rahhal, T. B., DeSimone, J. M., Pradeep, S., Han, H.-D., Napier, M. E., Miyake, T., Sood, A. K. |
| Jazyk: |
angličtina |
| Rok vydání: |
2014 |
| DOI: |
10.17615/zkyq-v482 |
| Popis: |
The purpose of this study was to investigate the antitumor effects of a combination of metronomic doses of a novel delivery vehicle, PLGA-PRINT nanoparticles containing docetaxel, and anti-angiogenic mEZH2 siRNA incorporated into chitosan nanoparticles. In vivo dose-finding studies and therapeutic experiments were conducted in well-established orthotopic mouse models of epithelial ovarian cancer. Antitumor effects were determined on the basis of reduction in mean tumor weight and number of metastatic tumor nodules in the animals. The tumor tissues from these in vivo studies were stained to evaluate the proliferation index (Ki67), apoptosis index (cleaved caspase 3), and microvessel density (CD31). The lowest dose of metronomic regimen (0.5 mg/kg) resulted in significant reduction in tumor growth. The combination of PLGA-PRINT-docetaxel and CH-mEZH2 siRNA showed significant antitumor effects in the HeyA8 and SKOV3ip1 tumor models (p |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
